The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer.

The Canadian journal of urology

Volumn 13 Suppl 2, Issue , 2006, Pages 68-71

  Pickles, Tom ^a   Pollack, Alan ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; HUMAN; MALE; PROSTATE TUMOR; RADIATION DOSE; REVIEW; RISK FACTOR;

ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS;

EID: 33747110728     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)